Elderly Man Gets Early Access to Weight-Loss Drug

 

by Pa Rock

Citizen Journalist

The Eli Lilly pharmaceutical company has reportedly developed a new weight-loss drug that is so effective in burning body fat that people are already clamoring for it - even though the drug is still in clinical trials and not available to the general public.  (I say "general public" because in a socially stratified society such as ours, money and position buy special access to everything from amusement park rides to Presidential pardons.  People are always buying their way to the front of the line.)

The weight-loss wonder drug is called Retatrutide and commonly referred to on social media as "Reta."  It is already the subject of a fast-growing black market trade, some of which is counterfeit and even dangerous.

On June 23rd (last Tuesday) the internet site, STAT News, ran a story about a 79-year-old male who had been granted "compassionate access" to Reta in April of 2026, years before it was likely to be available to the general public.   The reporter from STAT, Lizzy Lawrence, said that the elderly man had applied for the "compassionate use" designation through a program offered by the Food and Drug Administration (FDA), an organization that is part of the executive branch of the federal government - and ultimately under the control of the President of the United States.

Ms. Lawrence speculated that the person who received thespecial permission was possibly Donald Trump - who used that same process during his first term to gain early accesss to a COVID drug.   STAT and several news organizations made inquiries with the White House as to whether it was Trump who had been given the "compassionate use" designation for early access to Reta, but their requests for information were swatted away with suggestions that they take their questions to other government agencies such as the Department of Health and Human Services (HHS).

Finally, after it became apparent that the story wasn't going to quickly disappear, White House spokesman Kush Desai went on Twitter and denied the secret patient was Trump, and then, in typical White House fashion, attacked the original reporter, referring to her as a "gossip columnist."

Reporter Lizzy Lawrence said she based her speculation on three factors:

    1.  High level personnel were used to process the request whereas normally lower level employees would have handled the request.

    2.  When Eli Lilly offered this drug for the "compassionate use" program, they provided very little    information - and it was offered on a "single patient" basis when obesity is a common medical issue.

    3.  Trump had used the same process to gain early access to a drug during COVID.

The patient's medical justification for being allowed to take the drug before FDA approval was that he had the following conditions:

    1.  Refractory obesity.

    2.  Obstructive sleep apnea.

    3.  Pulmonary hypertension  (high blood pressure in the lungs).

In the event that the reclusive elderly patient turns out to have been Trump, the justification given for his use of Reta is some of the most revealing medical information that has been released on him to date.

Here are a couple of additional factors related to Donald Trump's obesity which are worth noting in this space.    In January of this year Trump told a reporter for the New York Times that he has never taken GLP-1 weight-loss drugs like Ozempic or Wegovy, though he admitted he "probably should."  And in their new book, Regime Change (out yesterday - and Pa Rock already has his copy!),  New York Times reporters Maggie Haberman and Jonathan Swan describe Trump's bedroom in the White House thusly:    

"A nighttime snacker, the President would frequently leave an array of empty potato chip bags, Starbucks wrappers, and ice cream cartons in the trash, or on the floor." 

The old man is eating ice cream in bed and then throwing his trash on the floor!   It's gonna take more that a wonder drug to trim that pork chop!